Iressa gains a positive opinion for lung cancer in the EU
This article was originally published in Scrip
Executive Summary
The EU's CHMP has recommended AstraZeneca's targeted oral therapy, gefitinib (Iressa), 250mg tablets, for use as first-line therapy in a subgroup of advanced lung cancer patients with a certain gene mutation.